Nifty 16912.25 (-1.65%)
Sensex 56747.14 (-1.65%)
Nifty Bank 35735.9 (-1.27%)
Nifty IT 34879.4 (-2.70%)
Nifty Financial Services 17596.7 (-1.03%)
Adani Ports 723.45 (-1.90%)
Asian Paints 3038.30 (-2.32%)
Axis Bank 663.10 (-1.47%)
B P C L 383.45 (-0.63%)
Bajaj Auto 3249.75 (-1.16%)
Bajaj Finance 6951.75 (-1.66%)
Bajaj Finserv 16893.45 (-3.40%)
Bharti Airtel 697.60 (-2.89%)
Britannia Inds. 3496.20 (-1.62%)
Cipla 894.95 (-1.87%)
Coal India 148.55 (-7.01%)
Divis Lab. 4646.80 (-2.32%)
Dr Reddys Labs 4498.70 (-2.13%)
Eicher Motors 2444.10 (-0.47%)
Grasim Inds 1660.75 (-2.53%)
H D F C 2768.80 (-0.10%)
HCL Technologies 1136.55 (-2.98%)
HDFC Bank 1503.80 (-0.64%)
HDFC Life Insur. 684.20 (-0.98%)
Hero Motocorp 2420.00 (-1.72%)
Hind. Unilever 2306.50 (-1.59%)
Hindalco Inds. 421.35 (-0.78%)
I O C L 120.95 (-1.02%)
ICICI Bank 709.55 (-0.94%)
IndusInd Bank 915.65 (-3.73%)
Infosys 1695.30 (-2.32%)
ITC 217.90 (-1.69%)
JSW Steel 642.85 (-0.26%)
Kotak Mah. Bank 1885.20 (-1.51%)
Larsen & Toubro 1782.65 (-1.03%)
M & M 822.15 (-1.77%)
Maruti Suzuki 7042.85 (-2.30%)
Nestle India 19016.50 (-1.58%)
NTPC 124.35 (-2.09%)
O N G C 143.35 (-1.75%)
Power Grid Corpn 202.00 (-1.99%)
Reliance Industr 2362.60 (-1.90%)
SBI Life Insuran 1148.50 (-1.50%)
Shree Cement 25612.35 (-1.16%)
St Bk of India 465.30 (-1.66%)
Sun Pharma.Inds. 737.15 (-1.95%)
Tata Consumer 747.60 (-3.45%)
Tata Motors 467.20 (-2.69%)
Tata Steel 1108.80 (-0.82%)
TCS 3536.40 (-2.86%)
Tech Mahindra 1551.75 (-2.61%)
Titan Company 2325.30 (-1.86%)
UltraTech Cem. 7214.60 (-1.61%)
UPL 716.55 (0.53%)
Wipro 624.50 (-2.54%)
GLENMARK

Glenmark Pharmaceuticals ..

₹493.3
Not a customer?

Open free demat account
& trade instantly

Investment Ratings

  • Master Rating:
  • Glenmark Pharms. (Nse) has an operating revenue of Rs. 11,759.00 Cr. on a trailing 12-month basis. An annual revenue growth of 2% is not great, Pre-tax margin of 13% is healthy, ROE of 13% is good. The company has a debt to equity of 55%, which is bit higher. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 66 which is a FAIR score but needs to improve its earnings, a RS Rating of 15 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D+ which indicates heavy supply, Group Rank of 149 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

EPS Strength

Price Strength

Buyer Demand

Group Rank

As per analysts rating in the last 6 months, the recommendation isHOLD Glenmark Pharma.

Glenmark Pharmaceuticals Ltd Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Ratings

Eps And Sales Estimates

Glenmark Pharmaceuticals Ltd Synopsis

NSE-Medical-Generic Drugs

Glenmark Pharma is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company’s Total Operating Revenue is Rs. 7567.93 Cr. and Equity Capital is Rs. 28.22 Cr. for the Year ended 31/03/2021. Glenmark Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 18/11/1977 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24299MH1977PLC019982 and registration number is 019982.
  • Market Cap

    INR 13,930.64 Cr

  • Sales

    INR 8,145.83 Cr

  • Shares in Float

    14.95 Cr

  • No of Funds

    284 K

  • Yield

    0.5%

  • Book Value

    0.95

  • U/D Vol Ratio

    1.3

  • LTDebt/Equity

    21%

  • Alpha

    -0.14

  • Beta

    1.05

Glenmark Pharmaceuticals Ltd Ownership
Glenmark Pharmaceuticals Ltd Management

Glenmark Pharmaceuticals Ltd Financials

INDICATORMar 2021Mar 2020Mar 2019Mar 2018Mar 2017
Total ShareHolders Funds Annual Cr 14809.50613226.26411942.08910391.4419436.619
Fixed Assets Annual Cr 1853.8931811.9591699.6782118.7971867.029
Total Non Current Assets Annual Cr 15708.40414527.70212001.5449389.628049.716
Total Current Assets Annual Cr 4909.1164423.8975141.1535875.2515950.83
Total Assets Annual Cr 20617.5218951.59917142.69715264.87114000.546
INDICATORMar 2021Mar 2020Mar 2019Mar 2018Mar 2017
Book Value Per Share Annual Rs 524.8433468.7338423.2231368.2688334.4302
ROE Annual % 11.1310.2413.589.7622.68
ROCE Annual % 11.7910.711.4110.7724.45
Total Debt to Total Equity Annual -----
EBDIT Annual Margin % 30.2128.4628.5923.7537.63

Glenmark Pharmaceuticals Ltd Technicals

EMA & SMA

CURRENT PRICE

493.3 (-1.15)

    • Bullish Moving Averages 0
    • Bearish Moving Averages 16

EMA

  • 20 Day

    509.84

  • 50 Day

    517.51

  • 100 Day

    529.27

  • 200 Day

    550.38

Glenmark Pharmaceuticals Ltd Resistance and support

502.02 PIVOT

  • First Resistance

    507.04

  • Second Resistance

    515.02

  • Third Resistance

    520.04

  • First Support

    494.04

  • Second Support

    489.02

  • Third Support

    481.04

  • RSI

    43.66

  • MFI

    49.85

  • MACD

    -3.06

  • MACD signal line

    -1.28

Glenmark Pharmaceuticals Ltd Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 794,953 16,256,789 20.45%
Week 1,420,664 36,695,746 25.83%
1 Month 2,124,447 49,988,244 23.53%
6 Month 1,894,859 53,567,675 28.27%

Glenmark Pharmaceuticals Ltd Price change analysis

-30.1

Over 1 month

Low High
457 551.8

-42.55

Over 3 month

Low High
457 551.8

-121.1

Over 6 months

Low High
457 690.95

-9.95

Over Year

Low High
442.05 690.95

Similar Stocks

News

GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under

Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 - S&P Global Ratings. With reference to the subject Read More

Accumulate Glenmark Pharmaceuticals target of Rs 575: Geojit

Geojit recommended accumulate rating on Glenmark Pharmaceuticals with a target price of Rs 575 in its research report dated November 18, 202 Read More

Neutral Glenmark Pharma; target of Rs 560: Motilal Oswal

Motilal Oswal recommended Neutral rating on Glenmark Pharma with a target price of Rs 560 in its research report dated November 15, 2021. Read More

GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under

Glenmark Pharmaceuticals makes it to the prestigious Dow Jones Sustainability Emerging Markets Index for the fourth consecutive year Read More

Earnings Call for Q2FY22 of Glenmark Pharmaceuticals Ltd.

Conference Call with Glenmark Pharmaceuticals Management and Analysts on Q2FY22 Performance and Outlook. Listen to the full earnings transcr Read More

Blogs

FAQs

Stock Directory-

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All 0-9